Lifestyle Intervention Cuts Cognitive Decline Risk in Older Adults Across Latin America, Trial Finds

A large randomized trial reported this week offers some of the clearest evidence yet that dementia risk isn't fixed, and that structured lifestyle programs can move the needle even in populations that clinical research has largely ignored until now.

The LatAm-FINGERS study, funded by the Alzheimer's Association, enrolled adults at elevated risk for cognitive decline and randomized them to either an intensive, coach-led multidomain program or a more flexible health-advice approach. The intervention combined physical activity, dietary changes, cognitive training, and social engagement, all adapted for local customs, languages, and community structures.

The results were reported July 13 at the Alzheimer's Association International Conference in London and published the same day in The Lancet. According to the trial abstract reviewed in The Lancet, a culturally adapted multidomain lifestyle intervention "resulted in greater cognitive improvements than a flexible health-advice intervention in older adults at risk of cognitive decline."

The trial enrolled 1,065 participants between the ages of 60 and 77 across 11 Latin American countries, according to reporting by MedicalXpress on the published trial. That makes it, as the researchers describe, the first large-scale brain health clinical trial designed specifically for Latin American communities.

The gains matter not just for the individuals in the study but for the global calculus on dementia prevention. The 2024 Lancet Commission on dementia prevention, intervention, and care had already estimated that roughly 45% of dementia cases worldwide could potentially be prevented or delayed by addressing 14 modifiable risk factors. That list includes hearing loss, physical inactivity, high LDL cholesterol, diabetes, social isolation, smoking, and untreated vision loss, among others.

But that 45% figure is an average across populations, and the burden isn't evenly distributed. According to the LatAm-FINGERS clinical trial registry, Latin America's potential for dementia reduction through lifestyle modification may be as high as 56%, reflecting the region's higher prevalence of vascular risk factors and lower average educational attainment.

The structured arm of LatAm-FINGERS outperformed the self-guided approach, which tracks with findings from the U.S. POINTER trial, a parallel study that reached similar conclusions in American adults. According to the Alzheimer's Association press release issued from the conference, the strongest cognitive gains were seen among participants who received structured support and coaching, not just general advice.

That distinction is clinically important. A sheet of pamphlets about Mediterranean eating and walking 30 minutes a day looks very different from a program with group sessions, moderated peer support, and personalized follow-up. The trial tested the latter, and it worked.

Researchers and the authors themselves are careful about what the findings do and don't show. According to MedicalXpress, the authors caution that the trial measured gains on cognitive tests rather than whether the program ultimately prevents dementia, and that longer follow-up is needed to confirm lasting clinical benefit. In other words, improved scores on a cognitive battery during a two-year window don't automatically translate to fewer dementia diagnoses a decade from now.

That caveat matters, but it shouldn't swamp the signal. These results extend the evidence base for multidomain lifestyle interventions beyond high-income, predominantly white trial populations. According to the trial abstract in The Lancet, the findings support "feasibility and scalability" of these approaches "to reduce cognitive decline risk amid the rapidly growing burden of dementia in low-income and middle-income countries."

Getting a culturally adapted, multisite clinical trial to function across 11 countries, including navigating transportation barriers and what the prior LatAm-FINGERS literature describes as risks of violence in certain regions, is itself a public health achievement. The structure that made it work, specifically group delivery, local dietary adaptation, and community recognition strategies, is likely inseparable from the outcomes it produced.

For neurologists and geriatricians managing patients at midlife with two or three of those 14 modifiable risk factors already in play, the message from this trial is consistent with what the FINGER network has been building toward for a decade: waiting for a drug is not the only strategy, and it may not be the most effective one available right now.

Sources cited:
- The Lancet, LatAm-FINGERS trial abstract (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01278-X/abstract)
- Alzheimer's Association press release via PR Newswire (https://www.prnewswire.com/news-releases/from-the-alzheimers-association-international-conference-2026-lifestyle-program-improves-brain-health-among-older-adults-at-risk-for-dementia-across-latin-america-302823398.html)
- MedicalXpress, trial coverage (https://medicalxpress.com/news/2026-07-year-lifestyle-older-adults-cognition.html)
- The Lancet Commission on Dementia Prevention 2024 (https://www.thelancet.com/commissions-do/dementia-prevention-intervention-and-care)
- LatAm-FINGERS clinical trial registry, MedPath (https://trial.medpath.com/clinical-trial/ef84dd245d47cd0d/nct06492967-latin-american-lifestyle-intervention-cognitive-impairment)